• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Verastem Stock After Earnings Improvement And New Share Offerings

    Simply Wall St·11/13/2026 11:31:49
    Listen to the news
    • Verastem reported third quarter 2026 revenue of US$24.01 million and a net loss of US$74.72 million, alongside multiple new equity and shelf security offerings filed on November 5, 2026.
    • The combination of higher reported revenue, reduced losses and fresh capital access indicates that management is attempting to balance commercial investment with funding flexibility as the oncology portfolio advances.
    • We will now look at how Verastem's improved revenue and new US$100 million at-the-market offering shape its investment narrative.

    Scan how Verastem's funding moves compare with other healthcare names that are raising capital and pushing pipelines forward by reviewing the hand picked 35 healthcare AI stocks in this space.

    Verastem Investment Narrative Recap

    To own Verastem, you need to be comfortable with a commercial oncology launch that is still funding meaningful R&D and reporting sizeable losses. The analyst consensus Narrative on Simply Wall St leans on the idea that focused exposure to RAS and MAPK driven cancers can support higher future revenue. The latest quarter shows higher reported sales and a smaller loss, but the key near term swing factor remains execution on AVMAPKI FAKZYNJA CO PACK uptake and access.

    On the risk side, Verastem is still loss making and had previously guided its cash runway only into the second half of 2026, so funding and dilution remain central concerns. Clinical progress in RAMP 205, RAMP 301 and VS 7375 is still the biggest operational uncertainty, because setbacks there could keep earnings under pressure and make the path to profitability longer, regardless of the recent quarterly numbers.

    The US$100 million at the market offering filed on November 5, 2026 looks most relevant to these results because it directly interacts with the cash runway and the scale of current losses. With nine month revenue of US$82.76 million and a net loss of US$145.99 million, additional access to equity capital gives Verastem more room to keep funding AVMAPKI FAKZYNJA CO PACK and its trials if internal cash flows stay negative.

    For you as a shareholder or potential investor, that ATM facility cuts both ways. It can reduce the risk that tight liquidity forces sudden spending cuts around RAMP 301 or the VS 7375 KRAS G12D program, which are key catalysts, but frequent issuance could be dilutive in a stock that has already seen substantial dilution in the past year and remains unprofitable on analyst forecasts.

    Verastem's current analyst framework points to forecast revenue of US$312.2 million and projected earnings of US$50.1 million by 2029, built on assumed yearly revenue growth of 52.8% and an earnings swing of roughly US$252.8 million from earnings today of a US$202.7 million loss.

    Uncover why Verastem's fair value indicates a 104% potential upside to its current price before sentiment around that discount shifts.

    NasdaqCM:VSTM 1-Year Stock Price Chart
    NasdaqCM:VSTM 1-Year Stock Price Chart

    Exploring Other Perspectives

    You have another lens to consider. The most bearish analysts focus on VS 7375 risk. They worry those KRAS G12D trials struggle to translate into approvals and broad use. Their earlier view included revenue of about US$266.3 million and earnings of roughly US$42.4 million by 2029, which is far more cautious than consensus. Those forecasts were set before this earnings and funding news, so you may want to compare how your expectations for Verastem line up and whether this update could eventually shift either story.

    Explore 4 other Verastem fair value estimates, including one that suggests as much as 67% downside from the current price.

    Reach Your Own Conclusion

    Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

    Looking for more investment ideas beyond Verastem?

    If Verastem is only one piece of your watchlist, it can help to scan for other opportunities with clear strengths in balance sheets, income potential, or overlooked quality. The Simply Wall St Screener lets you filter for exactly those types of stocks in a few clicks.